Agendia, Inc.: Agendia Research Shows Highest Risk MammaPrint Category Predicts Strongest Chemosensitivity in Women with Early-Stage HR+HER2- Breast Cancer
At the 2023 ASCO® Annual Meeting, Agendia will present data that demonstrates women within MammaPrint's highest risk category have the strongest sensitivity to chemotherapy and more aggressive tumor
Source: finanznachrichten.de
